Updated 2026 U. S.
blood cholesterol guidelines now recommend statin therapy for an estimated 87.5 million adults, nearly 57% of Americans aged 30 to 79 without established cardiovascular disease.
The new framework, published July 20 in JAMA, was developed by the American Heart Association, the American College of Cardiology, and nine partnering societies.
It expands the target age range from 40–75 to 30–79, lowers risk thresholds, and incorporates 30-year risk projections to identify early cardiovascular risks.
Analysis led by Dr. Timothy Anderson of the University of Pittsburgh found that 21.5 million adults are newly eligible under the updated guidance.
This newly eligible group is generally younger and has a lower average 10-year risk of 3.1%, compared to 6.1% under older standards.
Shift Toward Long-Term Risk Assessment
“The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients,” said Dr. Anderson.
Previously, people in their 30s and 40s with high cholesterol were often advised to focus on diet and exercise rather than medication, unless they had heart disease or high-risk conditions like diabetes.
The updated framework integrates the PREVENT equations, which recalibrate risk assessments and reclassify over one in five adults.
Research led by Allison Peng of Johns Hopkins University found that while risk classifications shift, the total proportion of older adults recommended for therapy remains steady at roughly 49.6%.
Under the new guidelines, 10-year cardiovascular risk is categorized as borderline at 3%, intermediate at 5%, and high at 10%.
Conditions such as advanced chronic kidney disease or HIV now carry greater weight in determining statin candidacy.
Personalized Decisions and Lifestyle Remain Key
“Eligibility means that statin therapy should be considered,” said Dr. Leana Wen, emergency physician and clinical associate professor at George Washington University.
She emphasized that qualifying for statins does not imply an automatic prescription, but rather prompts personalized discussions between patients and clinicians.
To evaluate candidacy, clinicians use a full lipid panel, medical history, and the PREVENT calculator.
Additional tools like coronary artery calcium CT scans help clarify risk for borderline or intermediate patients.
“The goal is to identify people who may benefit from reducing cholesterol earlier rather than waiting until their 10-year risk becomes high,” Dr. Wen added.
A third study in JAMA noted that 82.7% of high-risk primary prevention patients remain above recommended LDL target levels, highlighting persistent gaps in cholesterol management.
In an accompanying editorial, JAMA editors Philip Greenland and Karen Lasser urged healthcare systems to improve patient education, multidisciplinary care, and coverage access.
Lifestyle modifications including a healthy diet, regular exercise, weight management, and smoking cessation remain foundational for cardiovascular risk reduction.
“Lifestyle measures remain essential for everyone,” Dr. Wen said.
Although statins are the primary therapy, alternative non-statin treatments are emerging, including the recently FDA-approved oral PCSK9 inhibitor enlicitide.
“The first step is to know your numbers,” Dr. Wen concluded.
